- Home
- BARK vs ESPR Comparison
BARK vs ESPR Comparison
Compare BARK & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BARK
- ESPR
- Stock Information
- Founded
- BARK 2011
- ESPR 2008
- Country
- BARK United States
- ESPR United States
- Employees
- BARK N/A
- ESPR N/A
- Industry
- BARK Department/Specialty Retail Stores
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- BARK Consumer Discretionary
- ESPR Health Care
- Exchange
- BARK Nasdaq
- ESPR Nasdaq
- Market Cap
- BARK 244.9M
- ESPR 220.0M
- IPO Year
- BARK N/A
- ESPR 2013
- Fundamental
- Price
- BARK $0.86
- ESPR $2.17
- Analyst Decision
- BARK Strong Buy
- ESPR Buy
- Analyst Count
- BARK 3
- ESPR 6
- Target Price
- BARK $2.50
- ESPR $6.50
- AVG Volume (30 Days)
- BARK 751.0K
- ESPR 5.2M
- Earning Date
- BARK 08-07-2025
- ESPR 08-05-2025
- Dividend Yield
- BARK N/A
- ESPR N/A
- EPS Growth
- BARK N/A
- ESPR N/A
- EPS
- BARK N/A
- ESPR N/A
- Revenue
- BARK $470,831,000.00
- ESPR $268,125,000.00
- Revenue This Year
- BARK N/A
- ESPR $6.10
- Revenue Next Year
- BARK $9.47
- ESPR N/A
- P/E Ratio
- BARK N/A
- ESPR N/A
- Revenue Growth
- BARK N/A
- ESPR N/A
- 52 Week Low
- BARK $0.77
- ESPR $0.69
- 52 Week High
- BARK $2.56
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- BARK 49.24
- ESPR 73.45
- Support Level
- BARK $0.79
- ESPR $2.00
- Resistance Level
- BARK $0.86
- ESPR $2.14
- Average True Range (ATR)
- BARK 0.04
- ESPR 0.15
- MACD
- BARK 0.00
- ESPR 0.02
- Stochastic Oscillator
- BARK 63.02
- ESPR 95.08
About BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.